IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice.

IL-25 has been implicated in the initiation of type 2 immunity and in the protection against autoimmune inflammatory diseases. Recent studies have identified the novel innate lymphoid type 2 cells (ILC2s) as an IL-25 target cell population. The purpose of this study was to evaluate if IL-25 has any...

Full description

Bibliographic Details
Main Authors: Polyxeni T Mantani, Pontus Dunér, Eva Bengtsson, Ragnar Alm, Irena Ljungcrantz, Ingrid Söderberg, Lena Sundius, Fong To, Jan Nilsson, Harry Björkbacka, Gunilla Nordin Fredrikson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4309452?pdf=render
id doaj-3ea2bfd76251400c9387235ccc16e382
record_format Article
spelling doaj-3ea2bfd76251400c9387235ccc16e3822020-11-25T02:01:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01101e011725510.1371/journal.pone.0117255IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice.Polyxeni T MantaniPontus DunérEva BengtssonRagnar AlmIrena LjungcrantzIngrid SöderbergLena SundiusFong ToJan NilssonHarry BjörkbackaGunilla Nordin FredriksonIL-25 has been implicated in the initiation of type 2 immunity and in the protection against autoimmune inflammatory diseases. Recent studies have identified the novel innate lymphoid type 2 cells (ILC2s) as an IL-25 target cell population. The purpose of this study was to evaluate if IL-25 has any influence on atherosclerosis development in mice.Administration of 1 μg IL-25 per day for one week to atherosclerosis-prone apolipoprotein (apo)E deficient mice, had limited effect on the frequency of T cell populations, but resulted in a large expansion of ILC2s in the spleen. The expansion was accompanied by increased levels of anti-phosphorylcholine (PC) natural IgM antibodies in plasma and elevated levels of IL-5 in plasma and spleen. Transfer of ILC2s to apoE deficient mice elevated the natural antibody-producing B1a cell population in the spleen. Treatment of apoE/Rag-1 deficient mice with IL-25 was also associated with extensive expansion of splenic ILC2s and increased plasma IL-5, suggesting ILC2s to be the source of IL-5. Administration of IL-25 in IL-5 deficient mice resulted in an expanded ILC2 population, but did not stimulate generation of anti-PC IgM, indicating that IL-5 is not required for ILC2 expansion but for the downstream production of natural antibodies. Additionally, administration of 1 μg IL-25 per day for 4 weeks in apoE deficient mice reduced atherosclerosis in the aorta both during initiation and progression of the disease.The present findings demonstrate that IL-25 has a protective role in atherosclerosis mediated by innate responses, including ILC2 expansion, increased IL-5 secretion, B1a expansion and natural anti-PC IgM generation, rather than adaptive Th2 responses.http://europepmc.org/articles/PMC4309452?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Polyxeni T Mantani
Pontus Dunér
Eva Bengtsson
Ragnar Alm
Irena Ljungcrantz
Ingrid Söderberg
Lena Sundius
Fong To
Jan Nilsson
Harry Björkbacka
Gunilla Nordin Fredrikson
spellingShingle Polyxeni T Mantani
Pontus Dunér
Eva Bengtsson
Ragnar Alm
Irena Ljungcrantz
Ingrid Söderberg
Lena Sundius
Fong To
Jan Nilsson
Harry Björkbacka
Gunilla Nordin Fredrikson
IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice.
PLoS ONE
author_facet Polyxeni T Mantani
Pontus Dunér
Eva Bengtsson
Ragnar Alm
Irena Ljungcrantz
Ingrid Söderberg
Lena Sundius
Fong To
Jan Nilsson
Harry Björkbacka
Gunilla Nordin Fredrikson
author_sort Polyxeni T Mantani
title IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice.
title_short IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice.
title_full IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice.
title_fullStr IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice.
title_full_unstemmed IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice.
title_sort il-25 inhibits atherosclerosis development in apolipoprotein e deficient mice.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description IL-25 has been implicated in the initiation of type 2 immunity and in the protection against autoimmune inflammatory diseases. Recent studies have identified the novel innate lymphoid type 2 cells (ILC2s) as an IL-25 target cell population. The purpose of this study was to evaluate if IL-25 has any influence on atherosclerosis development in mice.Administration of 1 μg IL-25 per day for one week to atherosclerosis-prone apolipoprotein (apo)E deficient mice, had limited effect on the frequency of T cell populations, but resulted in a large expansion of ILC2s in the spleen. The expansion was accompanied by increased levels of anti-phosphorylcholine (PC) natural IgM antibodies in plasma and elevated levels of IL-5 in plasma and spleen. Transfer of ILC2s to apoE deficient mice elevated the natural antibody-producing B1a cell population in the spleen. Treatment of apoE/Rag-1 deficient mice with IL-25 was also associated with extensive expansion of splenic ILC2s and increased plasma IL-5, suggesting ILC2s to be the source of IL-5. Administration of IL-25 in IL-5 deficient mice resulted in an expanded ILC2 population, but did not stimulate generation of anti-PC IgM, indicating that IL-5 is not required for ILC2 expansion but for the downstream production of natural antibodies. Additionally, administration of 1 μg IL-25 per day for 4 weeks in apoE deficient mice reduced atherosclerosis in the aorta both during initiation and progression of the disease.The present findings demonstrate that IL-25 has a protective role in atherosclerosis mediated by innate responses, including ILC2 expansion, increased IL-5 secretion, B1a expansion and natural anti-PC IgM generation, rather than adaptive Th2 responses.
url http://europepmc.org/articles/PMC4309452?pdf=render
work_keys_str_mv AT polyxenitmantani il25inhibitsatherosclerosisdevelopmentinapolipoproteinedeficientmice
AT pontusduner il25inhibitsatherosclerosisdevelopmentinapolipoproteinedeficientmice
AT evabengtsson il25inhibitsatherosclerosisdevelopmentinapolipoproteinedeficientmice
AT ragnaralm il25inhibitsatherosclerosisdevelopmentinapolipoproteinedeficientmice
AT irenaljungcrantz il25inhibitsatherosclerosisdevelopmentinapolipoproteinedeficientmice
AT ingridsoderberg il25inhibitsatherosclerosisdevelopmentinapolipoproteinedeficientmice
AT lenasundius il25inhibitsatherosclerosisdevelopmentinapolipoproteinedeficientmice
AT fongto il25inhibitsatherosclerosisdevelopmentinapolipoproteinedeficientmice
AT jannilsson il25inhibitsatherosclerosisdevelopmentinapolipoproteinedeficientmice
AT harrybjorkbacka il25inhibitsatherosclerosisdevelopmentinapolipoproteinedeficientmice
AT gunillanordinfredrikson il25inhibitsatherosclerosisdevelopmentinapolipoproteinedeficientmice
_version_ 1724957333331640320